Group 1 - Thermo Fisher Scientific Inc. (NYSE:TMO) is recognized as one of the 10 Best Diagnostics and Research Stocks to Buy according to analysts [1] - The company has entered into a strategic collaboration with AIM ImmunoTech to design a pivotal Phase 3 clinical trial for Ampligen, targeting late-stage pancreatic cancer, leveraging Phase 2 results from the DURIPANC trial [2] - U.S. President Donald Trump announced a visit to Thermo Fisher Scientific in Ohio, highlighting the company's $2 billion investment in U.S. manufacturing, which is expected to repatriate high-paying jobs and strengthen domestic supply chains [3] Group 2 - As of March 21, 2026, CNN reported a consensus Buy rating for Thermo Fisher Scientific, with a 1-year average upside potential of 40.71%, based on analysis from 29 analysts [4] - Founded in 2006, Thermo Fisher Scientific specializes in life sciences and clinical research, providing analytical instruments, clinical development solutions, specialty diagnostics, and various laboratory services [4]

Core Viewpoint - AIM ImmunoTech Inc. has entered into an agreement with Thermo Fisher Scientific to design a Phase 3 clinical trial for its drug Ampligen, aimed at treating late-stage pancreatic cancer, following promising results from the ongoing Phase 2 DURIPANC trial [1][2]. Group 1: Clinical Trial Developments - The Phase 2 DURIPANC clinical trial, which involves Ampligen and AstraZeneca's durvalumab, is showing positive results in terms of Progression-Free Survival (PFS), Overall Survival (OS), and safety [3]. - The DURIPANC study is an exploratory, open-label trial expected to enroll up to 25 subjects, conducted in collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands [3]. Group 2: Company Strategy and Goals - AIM's CEO emphasized the importance of moving forward with the development of Ampligen for pancreatic cancer, highlighting the drug's potential to address a significant unmet medical need [2]. - The company has published an updated corporate presentation outlining its goal for new drug approval for Ampligen, detailing its research and development efforts in pancreatic cancer [2]. Group 3: Product Information - Ampligen (rintatolimod) is described as a dsRNA and highly selective TLR3 agonist immuno-modulator, which has demonstrated broad-spectrum activity in clinical trials [4].

AIM ImmunoTech Conference Summary Company Overview - **Company**: AIM ImmunoTech (NYSEAM:AIM) - **Focus**: Development of Ampligen for the treatment of pancreatic cancer, a significant unmet medical need [1][3] Core Points and Arguments Strategic Focus on Pancreatic Cancer - AIM ImmunoTech has refined its development focus to prioritize pancreatic cancer due to its high lethality and lack of effective therapies [8][15] - The company believes Ampligen can alter the immunosuppressive status of tumors, leading to therapeutic effects in solid tumors, particularly pancreatic cancer [8][9] Market Need and Opportunity - Pancreatic cancer results in over 100,000 deaths annually in the U.S. and EU, with more than 450,000 deaths worldwide [11][13] - The company sees a moral obligation to address this unmet medical need, as current therapies are inadequate [9][15] - Ampligen has shown potential to extend overall survival beyond historical controls, with a median extension of over 8 months [39][84] Clinical Development and Data - The company has treated approximately 75 subjects in its phase II trials, demonstrating a strong safety profile and positive efficacy data [18][19][39] - Ampligen is positioned as both a monotherapy and a combination therapy, enhancing the effectiveness of checkpoint inhibitors [32][34] Business Model and Regulatory Strategy - AIM ImmunoTech aims to develop Ampligen to a stage suitable for acquisition by a larger pharmaceutical company [16][17] - The company has received orphan drug designations from the U.S. and EU, providing market exclusivity for an extended period post-approval [16][67] - The business model is supported by a strong intellectual property portfolio and positive clinical results [62][68] Future Plans and Milestones - The company is planning to transition from phase II to phase III trials, with a focus on designing a robust trial protocol [19][46] - AIM ImmunoTech anticipates announcing specific milestones related to the completion of phase II and the design of phase III trials [54][76] Additional Important Content - The company has collaborated with major pharmaceutical companies and research institutes, enhancing its credibility and resource access [25][24] - Ampligen's mechanism of action involves restoring the immune system, which is often compromised in cancer patients, thus improving their quality of life [28][30] - The company emphasizes the importance of designing trials that ensure success and drug approval, leveraging data from previous studies to inform current strategies [40][45] Conclusion - AIM ImmunoTech is strategically positioned to address a critical need in pancreatic cancer treatment with its lead product, Ampligen. The company is focused on advancing its clinical trials and securing partnerships to enhance its market presence and therapeutic impact [88][90]

Core Viewpoint - AIM ImmunoTech is set to present its lead program, Ampligen, for the treatment of pancreatic cancer during a virtual investor event on February 19, 2026, highlighting its clinical and regulatory strategy [1][2]. Group 1: Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing Ampligen (rintatolimod) for late-stage pancreatic cancer, addressing a significant global health issue [4]. - Ampligen is characterized as a dsRNA and highly selective TLR3 agonist immuno-modulator, demonstrating broad-spectrum activity in clinical trials [4]. Group 2: Event Details - Thomas K. Equels, the CEO of AIM, will participate in a Virtual Investor Closing Bell Event on February 19, 2026, at 4:00 PM ET [1]. - The event will emphasize the ongoing DURIPANC clinical trial, which involves a collaboration with AstraZeneca, combining Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), for treating metastatic pancreatic cancer [2]. - A live video webcast of the presentation will be available on the company's website, with a replay accessible for 90 days after the event [3].

As filed with the Securities and Exchange Commission on February 10, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIM ImmunoTech Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 52-0845822 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Nu ...

AIM ImmunoTech Conference Summary Company Overview - **Company**: AIM ImmunoTech (NYSEAM:AIM) - **Lead Asset**: Ampligen, a drug with potential in immuno-oncology, effective as both a monotherapy and a synergistic enhancer to checkpoint inhibitors across various solid tumors [8][12] Core Points and Arguments - **Ampligen's Potential**: - Demonstrated strong impact in improving response rates for patients who are refractory to checkpoint inhibitors [8] - Alters tumor microenvironment to enhance visibility to immune system, transforming "cold tumors" into "hot tumors" [11][12] - **Strategic Focus on Pancreatic Cancer**: - AIM has prioritized pancreatic cancer as its lead indication due to the high unmet medical need and potential for significant impact on patient survival [13][15] - The company aims to leverage its data showing Ampligen's ability to extend overall survival in pancreatic cancer, both as a monotherapy and in combination with AstraZeneca's Durvalumab [15][19] - Orphan drug designations received in the U.S. and Europe provide market exclusivity, enhancing the business opportunity [16][17] - **Market Context**: - Over 500,000 deaths annually from pancreatic cancer, with a low survival rate, highlighting the critical need for effective treatments [19] - The oncology sector is where significant biotech deals occur, with potential for billion-dollar partnerships [14][28] - **Clinical and Regulatory Strategy**: - AIM is working towards initiating a Phase 3 trial in pancreatic cancer, ideally in conjunction with checkpoint inhibitors [24][25] - The company has treated 57 subjects, demonstrating the ability to extend overall survival beyond standard care [25] - **Upcoming Milestones**: - Anticipation of a positive year-end report, which is expected to be a significant inflection point for the company [28] - Plans to find a big pharma partner to support the Phase 3 trial and capitalize on the research and development efforts [26][28] Other Important Content - **Collaborations**: - Successful collaborations with Merck and AstraZeneca have been crucial for advancing Ampligen's development [30] - Data from independent research institutions supports the efficacy of Ampligen in various cancers, not limited to pancreatic cancer [29][30] - **Quality of Life Considerations**: - Ampligen is noted for improving the quality of life for patients undergoing treatment, which is particularly important for those facing severe malignancies [15][16] - **Company's Position**: - AIM is a small biotech company with limited resources but is making significant strides in oncology research [31] - The CEO expressed gratitude towards collaborators, investors, and the research community for their support [39][40] This summary encapsulates the key insights from the AIM ImmunoTech conference, focusing on the company's strategic direction, clinical developments, and market opportunities in the context of pancreatic cancer and broader oncology applications.

Core Insights - AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-based therapies, with its flagship product Ampligen being explored for multiple therapeutic applications [1] - AIM demonstrates exceptional capital efficiency with a Return on Invested Capital (ROIC) of 443.97%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.83%, resulting in a ROIC to WACC ratio of 76.10 [2][6] - In contrast, AIM's peers, including Aytu BioPharma, iBio, Co-Diagnostics, Cocrystal Pharma, and NanoViricides, show negative ROIC to WACC ratios, indicating inefficiencies in capital utilization [3][4][5][6] Company Performance - AIM's ROIC of 443.97% indicates effective use of capital to generate substantial returns, setting it apart from its peers in the biotechnology sector [2][6] - The company's ROIC to WACC ratio of 76.10 highlights its ability to generate returns far exceeding its cost of capital, showcasing strong capital efficiency [2][6] Peer Comparison - Aytu BioPharma has a ROIC of -2.78% and a WACC of 18.15, resulting in a negative ROIC to WACC ratio of -0.15, indicating capital inefficiency [3] - iBio reports a ROIC of -117.47% and a WACC of 6.80, leading to a negative ROIC to WACC ratio of -17.28, further illustrating struggles in capital efficiency [4] - Co-Diagnostics and Cocrystal Pharma also exhibit negative ROIC to WACC ratios of -13.01 and -13.80, respectively, highlighting ongoing challenges in generating adequate returns [4] - NanoViricides shows a ROIC of -111.71% and a WACC of 9.11, resulting in a negative ROIC to WACC ratio of -12.27, underscoring the difficulties faced by AIM's peers [5]

Core Insights - AIM ImmunoTech Inc. announced the publication of a peer-reviewed article in the Journal for ImmunoTherapy of Cancer, demonstrating a positive combination effect of its drug Ampligen and interferon-alpha on tumor growth and subject survival [1][3] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. Its lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [4]

Group 1 - AIM ImmunoTech Inc. is recognized as a fundamentally strong penny stock with a 'Buy' rating and a price target of $6.00, indicating a potential upside of nearly 133% [1] - The company presented positive progress from its Ampligen clinical program in pancreatic cancer at a recent symposium, highlighting its ongoing research efforts [2] - CEO Thomas K. Equels emphasized the potential of Ampligen for treating late-stage metastatic and locally advanced pancreatic cancer, addressing a significant unmet medical need [3] Group 2 - AIM ImmunoTech is an immuno-pharma company based in Ocala, Florida, focusing on developing solutions for various cancers, viral diseases, and immune deficiency disorders [3]

Core Insights - AIM ImmunoTech Inc. will present significant clinical advancements of its drug Ampligen at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care in Warsaw, Poland, focusing on pancreatic cancer and other solid tumors [1][2] - The presentations will include data from the ongoing Phase 2 clinical trial for pancreatic cancer and the positive therapeutic effects of Ampligen on endometriosis, which is linked to ovarian cancer [1][3] Oncology - AIM will showcase data from its pancreatic cancer Early Access Program and the Phase 2 clinical trial at Erasmus Medical Center, highlighting the DURIPANC study that evaluates the combination of Ampligen and AstraZeneca's durvalumab for late-stage metastatic pancreatic cancer [3][4] - Preliminary results from the DURIPANC study indicate that Ampligen is well-tolerated, with promising early signs of improved progression-free survival (PFS) and overall survival (OS) compared to historical data [4][6] - Dr. Kalinski will discuss Ampligen's efficacy in treating various solid tumors, including late-stage recurrent ovarian cancer and triple-negative breast cancer, emphasizing the unmet healthcare needs these therapies address [5] Endometriosis - The upcoming presentation on endometriosis will analyze data from AIM's clinical trials for Chronic Fatigue Syndrome, revealing that approximately 80% of female participants experienced symptom improvement, highlighting Ampligen's potential in treating endometriosis [7][9] - Endometriosis affects around 190 million women globally and is associated with chronic pain and infertility, underscoring the need for new treatment options beyond radical surgeries [8] Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen being a first-in-class investigational drug that acts as a TLR3 agonist [10]